
Kodiak Sciences Inc
KODHealthcare|Biotechnology|USA
$41.28
+1.23 (+3.07%)
Tangible Book
$1.80
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
null,
47.9,
236.31,
497.93,
870.81
],
"ebit_estimate": [
-245.42,
-227.18,
-74.26,
103.32,
399.18
],
"ebitda_estimate": [
-244.58,
-224.05,
-37.72,
null,
null
],
"net_income_estimate": [
-240.72,
-221.07,
-67.06,
107.66,
367.07
],
"per_share_eps_estimate": [
-3.75,
-3.12,
-0.86,
1.17,
4.01
],
"eps_nri_estimate": [
-3.74,
-3.12,
-0.86,
1.17,
4.01
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
3.51,
4.18,
4.72,
null,
null
],
"pretax_income_estimate": [
-240.72,
-221.07,
-67.06,
111.66,
414.36
],
"operating_cash_flow_per_share_estimate": [
-3.31,
-2.76,
-0.38,
null,
null
],
"roa_estimate": [
-79.7,
-83,
null,
null,
null
],
"roe_estimate": [
-168.99,
-214.03,
-9.97,
null,
null
],
"gross_margin_estimate": [
null,
87.5,
89.08,
null,
null
],
"operating_cash_flow_estimate": [
-204.44,
-170.73,
-23.51,
null,
null
],
"pettm_estimate": [
0,
0,
0,
35.43,
10.31
],
"long_term_growth_rate_mean": 39.56,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 39.57,
"future_eps_nri_estimate_growth": 39.56,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 29.71,
"future_ebitda_estimate_growth": 41.28,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 31.49,
"future_pretax_income_estimate_growth": 31.49,
"future_book_value_per_share_estimate_growth": 22.44,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 54.56,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 44.58
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202712"
],
"revenue_estimate": [
null,
null,
null,
null
],
"ebit_estimate": [
-60.34,
-61.82,
-63.43,
null
],
"ebitda_estimate": [
-60.07,
-62.21,
-64.55,
null
],
"net_income_estimate": [
-59.22,
-60.82,
-62.32,
-64.95
],
"per_share_eps_estimate": [
-0.96,
-0.92,
-0.93,
null
],
"eps_nri_estimate": [
-0.96,
-0.93,
-0.92,
null
],
"dividend_estimate": [
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null
],
"pretax_income_estimate": [
-59.22,
-60.82,
-62.32,
-64.95
],
"operating_cash_flow_per_share_estimate": [
-0.92,
-0.86,
-0.86,
null
],
"roa_estimate": [
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
-56.91,
-53.2,
-53.2,
null
],
"pettm_estimate": [
null,
null,
null,
null
],
"long_term_growth_rate_mean": 39.56,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 39.57,
"future_eps_nri_estimate_growth": 39.56,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 29.71,
"future_ebitda_estimate_growth": 41.28,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 31.49,
"future_pretax_income_estimate_growth": 31.49,
"future_book_value_per_share_estimate_growth": 22.44,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 54.56,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 44.58
}